Clinical TrialAug 6, 2026, 08:05 AM
Vivani Medical fully enrolls & doses all in SLIM-1 Phase 1 trial
AI Summary
Vivani Medical, Inc. announced the full enrollment and successful initial dosing of all 20 participants in its SLIM-1™ Phase 1 trial for NPM-139, a miniature subdermal semaglutide implant. Dosing commenced ahead of schedule, with all insertion procedures completed without issues. The trial, which compares NPM-139 to Wegovy®, aims to assess safety, tolerability, and pharmacokinetics in GLP-1 naïve participants, with top-line data expected in November 2026. CEO Adam Mendelsohn highlighted the company's commitment to advancing GLP-1 product candidates and anticipates initiating a Phase 2 trial in 2027.
Key Highlights
- Vivani Medical fully enrolled and dosed all 20 participants in its SLIM-1™ Phase 1 trial for NPM-139.
- Initial dosing commenced ahead of schedule, with the first 10 participants dosed on July 29.
- The SLIM-1™ trial evaluates NPM-139, a semaglutide implant, against Wegovy® (semaglutide injection).
- Trial assesses safety, tolerability, and pharmacokinetics in 20 GLP-1 naïve participants in Australia.
- Top-line data from the Phase 1 trial is expected in November 2026.
- Vivani Medical anticipates initiating a Phase 2 dose-ranging trial in 2027.
- NPM-139 is designed to provide 6-12 months of continuous drug delivery using NanoPortal™ technology.
- Preclinical studies demonstrated sustainable 20% weight reduction in animal models for NPM-139.
Price Impact
More from VANI